Literature DB >> 9748132

Limitations of the reverse transcription-polymerase chain reaction method for the detection of carcinoembryonic antigen-positive tumor cells in peripheral blood.

Y Ko1, M Klinz, G Totzke, I Gouni-Berthold, A Sachinidis, H Vetter.   

Abstract

To examine the limitations of reverse transcription (RT)-PCR for the detection of circulating tumor cells in blood, we established a RT-PCR for carcinoembryonic antigen (CEA). Whole blood (10(7) nucleated cells) was mixed with cells from the colon cancer cell line LS174T (concentrations ranging from 0 to 10(6) cells). RT-PCR was performed to detect CEA mRNA in blood under various conditions. Healthy blood donors (n = 24) were examined by the established method for detecting CEA mRNA in blood. We were able to show that there is a detection limit for RT-PCR of 10 tumor cells in total and of 1 tumor cell in 10(5) nucleated cells. To obtain these results, a high number of PCR cycles (first PCR, 30 cycles; nested PCR, 45 cycles) was required. Under these PCR conditions, we found a positive PCR signal in 33% of healthy blood donors (n = 8). To overcome this problem, we reduced the nested PCR to 35 cycles. At that point, none of the controls showed a positive signal for CEA, and there was a subsequent decrease of the detection limit to 1 tumor cell in 10(2)-10(3) nucleated cells, lower than the detection limit of an immunocytological examination (1 tumor cell in 10(4) nucleated cells). When the amplification was performed with the tumor cells only and with no nucleated blood cells present, under exactly the same conditions, there was still a detection limit of 1 tumor cell in 106 nucleated cells. Our data clearly show that there is a severe loss of expected sensitivity of RT-PCR if it is performed in blood or nucleated blood cells. We conclude that PCR for CEA mRNA expression is not more sensitive than immunocytology and is, furthermore, plagued by the problem of a high percentage of false positive results.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9748132

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer.

Authors:  Ulrich Guller; Paul Zajac; Annelies Schnider; Beatrix Bösch; Stefan Vorburger; Markus Zuber; Giulio Cesare Spagnoli; Daniel Oertli; Robert Maurer; Urs Metzger; Felix Harder; Michael Heberer; Walter Richard Marti
Journal:  Ann Surg       Date:  2002-12       Impact factor: 12.969

2.  Disseminated cancer cells in the bone marrow: are they really there at all?

Authors:  Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2006       Impact factor: 7.370

3.  Specific detection of cytokeratin 20-positive cells in blood of colorectal and breast cancer patients by a high sensitivity real-time reverse transcriptase-polymerase chain reaction method.

Authors:  Giuliana Giribaldi; Simone Procida; Daniela Ulliers; Franca Mannu; Roberta Volpatto; Giorgia Mandili; Laura Fanchini; Oscar Bertetto; Gianruggero Fronda; Luigi Simula; Elena Rimini; Giovanni Cherchi; Lisa Bonello; Milena Maria Maule; Francesco Turrini
Journal:  J Mol Diagn       Date:  2006-02       Impact factor: 5.568

4.  Limitations of cytokeratin 20 RT-PCR to detect disseminated tumour cells in blood and bone marrow of patients with colorectal cancer: expression in controls and downregulation in tumour tissue.

Authors:  F A Vlems; J H S Diepstra; I M H A Cornelissen; T J M Ruers; M J L Ligtenberg; C J A Punt; J H J M van Krieken; Th Wobbes; G N P van Muijen
Journal:  Mol Pathol       Date:  2002-06

5.  The Evolving Role of Circulating Tumor Cells in the Personalized Management of Breast Cancer: from Enumeration to Molecular Characterization.

Authors:  Sasmit Sarangi; Kailash Mosulpuria; Michaela J Higgins; Aditya Bardia
Journal:  Curr Breast Cancer Rep       Date:  2014-09

6.  The clinical significance of ascitic fluid CEA in advanced gastric cancer with ascites.

Authors:  Minkyu Jung; Hei-Cheul Jeung; Sung Sook Lee; Jun Yong Park; Soojung Hong; Soo Hyeon Lee; Sung Hoon Noh; Hyun Cheol Chung; Sun Young Rha
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-23       Impact factor: 4.553

Review 7.  CD133: a cancer stem cells marker, is used in colorectal cancers.

Authors:  Fei Ren; Wei-Qi Sheng; Xiang Du
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

8.  Occult disseminated tumor cells in lymph nodes of patients with gastric carcinoma. A critical appraisal of assessment and relevance.

Authors:  Peter Scheunemann; Nikolas H Stoecklein; Kai Hermann; Alexander Rehders; Claus F Eisenberger; Wolfram T Knoefel; Stefan B Hosch
Journal:  Langenbecks Arch Surg       Date:  2008-07-15       Impact factor: 3.445

Review 9.  Genetic detection of free cancer cells in the peritoneal cavity of the patient with gastric cancer: present status and future perspectives.

Authors:  Yoshiyuki Fujiwara; Yuichiro Doki; Hirokazu Taniguchi; Itsuro Sohma; Shuji Takiguchi; Hiroshi Miyata; Makoto Yamasaki; Morito Monden
Journal:  Gastric Cancer       Date:  2007-12-25       Impact factor: 7.370

10.  Occult tumor cells in lymph nodes as a predictor for tumor relapse in pancreatic adenocarcinoma.

Authors:  Peter Scheunemann; Nikolas H Stoecklein; Alexander Rehders; Minu Bidde; Sylvia Metz; Matthias Peiper; Claus F Eisenberger; Jan Schulte Am Esch; Wolfram T Knoefel; Stefan B Hosch
Journal:  Langenbecks Arch Surg       Date:  2007-08-18       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.